gw2974 profile

ID Source	ID
PubMed CID	6603857
CHEMBL ID	30432
SCHEMBL ID	1737530
CHEBI ID	95273
MeSH ID	M0493563

Synonym
AB01092265-01
SMP2_000301
EU-0100509
gw2974, >=98% (hplc), solid
NCGC00015468-01
lopac-g-0668
SMP2_000268
LOPAC0_000509
gw2974
NCGC00093907-01
NCGC00093907-02
gw282974x
NCGC00015468-02
n4-(1-benzyl-1h-indazol-5-yl)-n6,n6-dimethyl-pyrido[3,4-d]pyrimidine4-4,6-diamine
G 0668
NCGC00015468-04
CHEMBL30432 ,
n4-(1-benzyl-1h-indazol-5-yl)-n6,n6-dimethyl-pyrido[3,4-d]pyrimidine-4,6-diamine
bdbm50099963
4-n-(1-benzylindazol-5-yl)-6-n,6-n-dimethylpyrido[3,4-d]pyrimidine-4,6-diamine
HMS3261F19
NCGC00015468-05
CCG-204600
NCGC00015468-03
HMS3303J07
HMS3305C14
202272-68-2
LP00509
n4-(1-benzyl-1h-indazol-5-yl)-n6,n6-dimethyl-pyrido[3,4-d]pyrimidine-4,6-diamine
DYYZXRCFCVDSKD-UHFFFAOYSA-N
SCHEMBL1737530
tox21_500509
NCGC00261194-01
DTXSID40424963
CHEBI:95273
gw-2974
gw 2974
gw 974
J-013131
SR-01000075892-1
sr-01000075892
NCGC00015468-06
n6,n6-dimethyl-n4-[1-(phenylmethyl)-5-indazolyl]pyrido[3,4-d]pyrimidine-4,6-diamine
Q27167122
n4-(1-benzyl-1h-indazol-5-yl)-n6,n6-dimethylpyrido[3,4-d]pyrimidine-4,6-diamine
SDCCGSBI-0050493.P002
NCGC00015468-07
n4-(1-benzyl-1h-indazol-5-yl)-n6,n6-dimethyl-pyrido [3,4-d]pyrimidine-4,6-diamine
egfr/her2 inhibitor
nsc756204
nsc-756204
n4-(1-benzylindazol-5-yl)-n6,n6-dimethyl-pyrido[3,4-d]pyrimidine-4,6-diamine
AKOS040745835

Class	Description
pyridopyrimidine	Any organic heterobicyclic compound consisting of a pyridine ring ortho-fused at any position to a pyrimidine ring.

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	22.9833	AID1705; AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASE	Homo sapiens (human)	Potency	44.6684	AID485290
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	28.1838	AID2323
Chain A, Cruzipain	Trypanosoma cruzi	Potency	39.8107	AID1476
endonuclease IV	Escherichia coli	Potency	19.9526	AID1708
RGS12	Homo sapiens (human)	Potency	3.9811	AID879
15-lipoxygenase, partial	Homo sapiens (human)	Potency	25.1189	AID887
ATAD5 protein, partial	Homo sapiens (human)	Potency	27.4998	AID493106; AID493107
USP1 protein, partial	Homo sapiens (human)	Potency	31.6228	AID504865
NFKB1 protein, partial	Homo sapiens (human)	Potency	7.9433	AID895; AID928
GLS protein	Homo sapiens (human)	Potency	35.4813	AID624146
Microtubule-associated protein tau	Homo sapiens (human)	Potency	7.9433	AID1460
Thrombopoietin	Homo sapiens (human)	Potency	10.0000	AID917; AID918
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	35.4813	AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)	Homo sapiens (human)	Potency	0.7943	AID914; AID915
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	20.0526	AID1224819; AID1224820; AID1224821
Parkin	Homo sapiens (human)	Potency	23.1093	AID720572; AID720573
arylsulfatase A	Homo sapiens (human)	Potency	10.6910	AID720538
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	0.5788	AID504332
Bloom syndrome protein isoform 1	Homo sapiens (human)	Potency	1.1220	AID2364; AID2528
cytochrome P450 2D6 isoform 1	Homo sapiens (human)	Potency	31.6228	AID891
hexokinase-4 isoform 1	Homo sapiens (human)	Potency	0.7079	AID743205
peripheral myelin protein 22 isoform 1	Homo sapiens (human)	Potency	33.8078	AID1967
cellular tumor antigen p53 isoform a	Homo sapiens (human)	Potency	16.6038	AID902; AID924
cytochrome P450 2C19 precursor	Homo sapiens (human)	Potency	25.1189	AID899
cytochrome P450 2C9 precursor	Homo sapiens (human)	Potency	12.5893	AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1	Homo sapiens (human)	Potency	12.5893	AID894
chromobox protein homolog 1	Homo sapiens (human)	Potency	39.8107	AID488953
glucokinase regulatory protein	Homo sapiens (human)	Potency	0.7079	AID743205
guanine nucleotide-binding protein G(i) subunit alpha-1 isoform 1	Homo sapiens (human)	Potency	3.9811	AID879
mitogen-activated protein kinase 1	Homo sapiens (human)	Potency	7.1619	AID1454; AID1725; AID995
RAF proto-oncogene serine/threonine-protein kinase isoform b	Homo sapiens (human)	Potency	28.1838	AID1728
flap endonuclease 1	Homo sapiens (human)	Potency	11.9173	AID488816; AID588795
ras-related protein Rab-9A	Homo sapiens (human)	Potency	58.0479	AID485297
serine/threonine-protein kinase mTOR isoform 1	Homo sapiens (human)	Potency	26.1216	AID2668
tyrosine-protein kinase Yes	Homo sapiens (human)	Potency	0.2067	AID686947
DNA polymerase eta isoform 1	Homo sapiens (human)	Potency	28.1838	AID588591
geminin	Homo sapiens (human)	Potency	16.1276	AID463097; AID504364
DNA polymerase kappa isoform 1	Homo sapiens (human)	Potency	33.5875	AID588579
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	14.1254	AID1458
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	5.0119	AID884; AID885
M-phase phosphoprotein 8	Homo sapiens (human)	Potency	39.8107	AID488949
muscleblind-like protein 1 isoform 1	Homo sapiens (human)	Potency	12.5893	AID2675
muscarinic acetylcholine receptor M1	Rattus norvegicus (Norway rat)	Potency	21.4215	AID943; AID944
lamin isoform A-delta10	Homo sapiens (human)	Potency	0.0045	AID1487
neuropeptide S receptor isoform A	Homo sapiens (human)	Potency	10.0000	AID1461
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	5.0119	AID885
Integrin beta-3	Homo sapiens (human)	Potency	31.6228	AID924
Integrin alpha-IIb	Homo sapiens (human)	Potency	31.6228	AID924
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	5.0119	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	5.0119	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	5.0119	AID885
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	5.0119	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	5.0119	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	5.0119	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	5.0119	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	5.0119	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	5.0119	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	5.0119	AID885
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	Potency	12.5893	AID883
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	5.0119	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	5.0119	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	5.0119	AID885
Inositol monophosphatase 1	Rattus norvegicus (Norway rat)	Potency	11.2202	AID1457
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	5.0119	AID885
Ataxin-2	Homo sapiens (human)	Potency	39.8107	AID588378
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	5.0119	AID885
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	37.9330	AID485368

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
Epidermal growth factor receptor	Homo sapiens (human)	IC50	0.0727	AID1198818; AID66431; AID81335
RAF proto-oncogene serine/threonine-protein kinase	Homo sapiens (human)	IC50	49.0000	AID164358
Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)	IC50	0.0610	AID1198817; AID42142; AID79617
Cyclin-dependent kinase 1	Homo sapiens (human)	IC50	8.0000	AID53184
Receptor tyrosine-protein kinase erbB-2	Rattus norvegicus (Norway rat)	IC50	0.2040	AID197676; AID45095
Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)	IC50	50.0000	AID205319
5-hydroxytryptamine receptor 2A	Rattus norvegicus (Norway rat)	IC50	8.0000	AID53184
Cyclin-dependent kinase 2	Homo sapiens (human)	IC50	8.0000	AID53521
Serine hydroxymethyltransferase, mitochondrial	Homo sapiens (human)	IC50	2.4547	AID1619186
Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)	IC50	9.7000	AID108466
Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)	IC50	9.7000	AID108466
Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)	IC50	0.0200	AID197677
Potassium channel subfamily K member 9	Homo sapiens (human)	IC50	50.1000	AID1525558

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
Coelenterazine h 2-monooxygenase	Renilla reniformis (sea pansy)	AC50	23.0854	AID720834

Assay ID	Title	Year	Journal	Article
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 ISSN: 2472-5560	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID13169	Bioavailability was measured in rat	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID42142	Inhibition of erbB2 overexpressing BT 474 cell proliferation	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID79617	Inhibition of erbB2 overexpressing HB4a.e5.2 cell proliferation	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID9942	Bioavailability was measured in mouse	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID9904	Pharmacokinetic property (vdss) was measured in dog	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID108466	Inhibition of MAPK kinase (MEK)	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID1198818	Inhibition of EGFR intracellular domain (unknown origin) purified from a baculovirus expression system using Biotin-(amino hexonoic acid)-EEEEYFELVAKKK-CONH2 as substrate after 10 mins by scintillation counting in presence of [gamma-33P]ATP	2015	European journal of medicinal chemistry, May-05, Volume: 95ISSN: 1768-3254	Recent advances in the chemistry and biology of pyridopyrimidines.
AID1525558	Inhibition of human TASK3 expressed in HEK293 cells by Ti+ flux assay	2019	Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22 ISSN: 1520-4804	TASK Channels Pharmacology: New Challenges in Drug Design.
AID81335	Inhibition of EGF receptor overexpressing HN5 cell proliferation	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID205319	Inhibition of Src kinase	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID1198817	Inhibition of ErbB-2 intracellular domain (unknown origin) purified from a baculovirus expression system using Biotin-(amino hexonoic acid)-EEEEYFELVAKKK-CONH2 as substrate after 10 mins by scintillation counting in presence of [gamma-33P]ATP	2015	European journal of medicinal chemistry, May-05, Volume: 95ISSN: 1768-3254	Recent advances in the chemistry and biology of pyridopyrimidines.
AID7860	Pharmacokinetic property (vdss) was measured in mouse	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID53521	Inhibition of Cyclin-dependent kinase 2	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID197676	Inhibition of rat Receptor protein-tyrosine kinase erbB2	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID106357	Inhibition of MRC5 cell proliferation	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID9568	Pharmacokinetic property (Plasma clearance) was measured in mouse	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID9716	Half-life was measured in dog	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID10628	Half-life was measured in rat	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID10995	Pharmacokinetic property (Plasma clearance) was measured in rat	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID197677	Inhibition of erbB4 receptor	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID45095	Inhibition of erbB2 overexpressing Calu3 cell proliferation	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID164358	Inhibition of Raf kinase	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID53184	Inhibition of Cyclin-dependent kinase 1	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID11115	Pharmacokinetic property (vdss) was measured in rat	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID521220	Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay	2007	Nature chemical biology, May, Volume: 3, Issue:5 ISSN: 1552-4450	Chemical genetics reveals a complex functional ground state of neural stem cells.
AID9140	Bioavailability in dog	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID8560	Pharmacokinetic property (Plasma clearance) was measured in dog	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID66431	Inhibition of EGF receptor	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID7657	Half-life was measured in mouse	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID79616	Inhibition of RAS overexpressing HB4a.R4.2 cell proliferation	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11 ISSN: 0960-894X	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60ISSN: 1873-3913	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7 ISSN: 1932-6203	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173ISSN: 1872-9096	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173ISSN: 1872-9096	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay	2022	The Journal of biological chemistry, 08, Volume: 298, Issue:8 ISSN: 1083-351X
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16 ISSN: 0021-9258	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588378	qHTS for Inhibitors of ATXN expression: Validation	2022	The Journal of biological chemistry, 08, Volume: 298, Issue:8 ISSN: 1083-351X
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7 ISSN: 1945-7170	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7 ISSN: 1945-7170	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500 ISSN: 1946-6242	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7 ISSN: 1932-6203	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7 ISSN: 1554-8937	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500 ISSN: 1946-6242	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500 ISSN: 1946-6242	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173ISSN: 1872-9096	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4 ISSN: 2211-1247	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7 ISSN: 1932-6203	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID686947	qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 ISSN: 1464-3405	Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID652015	qHTS Assay for Inhibitors of Sea Pansy Luciferase from the GSK Published Protein Kinase Inhibitor Set	2013	PloS one, , Volume: 8, Issue:3 ISSN: 1932-6203	Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays.
AID652016	qHTS Assay for Inhibitors of Firefly Luciferase from the GSK Published Protein Kinase Inhibitor Set	2013	PloS one, , Volume: 8, Issue:3 ISSN: 1932-6203	Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6 ISSN: 1552-454X	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2022	Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 37, Issue:1 ISSN: 1475-6374
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6 ISSN: 1552-454X	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	12 (34.29)	29.6817
2010's	16 (45.71)	24.3611
2020's	7 (20.00)	2.80

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (5.71%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	33 (94.29%)	84.16%

Substance	Classes	Roles	Relationship Strength
pd 173074	aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist	low
pd 158780	aromatic amine; bromobenzenes; diamine; pyridopyrimidine; secondary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
pipemidic acid	amino acid; monocarboxylic acid; N-arylpiperazine; pyridopyrimidine; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor	low
piromidic acid	monocarboxylic acid; pyridopyrimidine; pyrrolidines; quinolone antibiotic; tertiary amino compound	antibacterial drug; DNA synthesis inhibitor	low
risperidone	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine	alpha-adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; psychotropic drug; second generation antipsychotic; serotonergic antagonist	low
trequinsin	pyridopyrimidine		low
pemirolast	pyridopyrimidine		low
ocaperidone	pyridopyrimidine		low
probon	pyridopyrimidine		low
8-methyl-4-oxo-3-pyrido[1,2-a]pyrimidinecarboxylic acid ethyl ester	pyridopyrimidine		low
paliperidone	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine; secondary alcohol		low
pd 173955	aryl sulfide; dichlorobenzene; methyl sulfide; pyridopyrimidine	tyrosine kinase inhibitor	low
2-imino-N,8-dimethyl-5-oxo-1-propan-2-yl-3-dipyrido[1,2-d-3',4'-f]pyrimidinecarboxamide	pyridopyrimidine		low
3-(benzenesulfonyl)-2-imino-1-(2-oxolanylmethyl)-5-dipyrido[1,2-d-3',4'-f]pyrimidinone	pyridopyrimidine		low
N-ethyl-2-imino-10-methyl-1-[(4-methylphenyl)methyl]-5-oxo-3-dipyrido[3,4-c-1',2'-f]pyrimidinecarboxamide	pyridopyrimidine		low
9,10-dimethoxy-2-(2-pyridinylmethylamino)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one	pyridopyrimidine		low
LSM-33283	pyridopyrimidine		low
LSM-20487	pyridopyrimidine		low
LSM-31933	pyridopyrimidine		low
N-cyclopentyl-2-imino-1-[3-(4-morpholinyl)propyl]-5-oxo-3-dipyrido[1,2-d-3',4'-f]pyrimidinecarboxamide	pyridopyrimidine		low
LSM-28559	pyridopyrimidine		low
N-(2-furanylmethyl)-2-imino-5-oxo-1-(2-phenylethyl)-3-dipyrido[1,2-d-3',4'-f]pyrimidinecarboxamide	pyridopyrimidine		low
2-imino-10-methyl-N-[2-(4-morpholinyl)ethyl]-5-oxo-1-(3-pyridinylmethyl)-3-dipyrido[3,4-c-1',2'-f]pyrimidinecarboxamide	pyridopyrimidine		low
3-(benzenesulfonyl)-2-imino-1-propyl-5-dipyrido[1,2-d-3',4'-f]pyrimidinone	pyridopyrimidine		low
7-methyl-4-oxo-2-[(phenylmethyl)amino]-3-pyrido[1,2-a]pyrimidinecarboxaldehyde	pyridopyrimidine		low
6-propan-2-yl-2-sulfanylidene-1,5,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-one	pyridopyrimidine		low
2-[[3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl]-oxomethyl]imino-1-(2-methylpropyl)-5-oxo-3-dipyrido[1,2-d-3',4'-f]pyrimidinecarboxylic acid ethyl ester	pyridopyrimidine		low
LSM-26967	pyridopyrimidine		low
2-[2-furanyl(oxo)methyl]imino-5-oxo-1-propan-2-yl-3-dipyrido[1,2-d-3',4'-f]pyrimidinecarboxylic acid ethyl ester	pyridopyrimidine		low
1-(2-methoxyethyl)-7-thiophen-2-yl-5-(trifluoromethyl)pyrido[2,3-d]pyrimidine-2,4-dione	pyridopyrimidine		low
1-butyl-2,4-dioxo-7-thiophen-2-yl-5-pyrido[2,3-d]pyrimidinecarboxylic acid ethyl ester	pyridopyrimidine		low
1-cyclopentyl-2-imino-10-methyl-5-oxo-N-(2-oxolanylmethyl)-3-dipyrido[3,4-c-1',2'-f]pyrimidinecarboxamide	pyridopyrimidine		low
2-methyl-1-cyclopropanecarboxylic acid (7-bromo-4-oxo-2-pyrido[1,2-a]pyrimidinyl)methyl ester	pyridopyrimidine		low
2-imino-1-[(4-methylphenyl)methyl]-5-oxo-N-(2-oxolanylmethyl)-3-dipyrido[1,2-d-3',4'-f]pyrimidinecarboxamide	pyridopyrimidine		low
2-(3-ethoxypropylamino)-8-methyl-5-oxo-N-(2-oxolanylmethyl)-3-dipyrido[1,2-pyrimidinecarboxamide	pyridopyrimidine		low
3-[2,4-dioxo-1-[(4-oxo-2-pyrido[1,2-a]pyrimidinyl)methyl]-3-quinazolinyl]-N-(2-furanylmethyl)propanamide	pyridopyrimidine		low
2-[(4-oxo-2-pyrido[1,2-a]pyrimidinyl)methylthio]-3-pyridinecarboxylic acid propan-2-yl ester	isopropyl ester; pyridopyrimidine		low
2-chloro-6-[4-morpholinyl(oxo)methyl]-11-pyrido[2,1-b]quinazolinone	pyridopyrimidine		low
N-(2-furanylmethyl)-1-[2-(2-hydroxyethoxy)ethyl]-2-imino-10-methyl-5-oxo-3-dipyrido[3,4-c-1',2'-f]pyrimidinecarboxamide	pyridopyrimidine		low
1-(3-ethoxypropyl)-2-[2-furanyl(oxo)methyl]imino-10-methyl-5-oxo-3-dipyrido[3,4-c-1',2'-f]pyrimidinecarboxylic acid ethyl ester	pyridopyrimidine		low
1-butyl-2-[2-furanyl(oxo)methyl]imino-10-methyl-5-oxo-3-dipyrido[3,4-c-1',2'-f]pyrimidinecarboxylic acid ethyl ester	pyridopyrimidine		low
2-benzoylimino-1-(2-furanylmethyl)-10-methyl-5-oxo-3-dipyrido[3,4-c-1',2'-f]pyrimidinecarboxylic acid ethyl ester	pyridopyrimidine		low
6-[4-oxo-2-[(4-oxo-2-pyrido[1,2-a]pyrimidinyl)methylthio]-3-thieno[3,2-d]pyrimidinyl]hexanoic acid	pyridopyrimidine		low
3-[4-oxo-2-[(4-oxo-2-pyrido[1,2-a]pyrimidinyl)methylthio]-3-thieno[3,2-d]pyrimidinyl]propanoic acid	pyridopyrimidine		low
2-chloro-8-[4-morpholinyl(oxo)methyl]-11-pyrido[2,1-b]quinazolinone	pyridopyrimidine		low
3-(3,4-dimethylphenyl)sulfonyl-2-imino-1-prop-2-enyl-5-dipyrido[1,2-e-4',3'-f]pyrimidinone	pyridopyrimidine		low
1-[2-(3,4-dimethoxyphenyl)ethyl]-2-imino-10-methyl-5-oxo-N-(2-oxolanylmethyl)-3-dipyrido[3,4-c-1',2'-f]pyrimidinecarboxamide	pyridopyrimidine		low
3-(4-fluorophenyl)sulfonyl-1-(2-furanylmethyl)-2-imino-10-methyl-5-dipyrido[3,4-c-1',2'-f]pyrimidinone	pyridopyrimidine		low
LSM-27960	pyridopyrimidine		low
1-[(7-chloro-4-oxo-2-pyrido[1,2-a]pyrimidinyl)methyl]-3-(3-fluoro-4-methylphenyl)thieno[3,2-d]pyrimidine-2,4-dione	pyridopyrimidine		low
LSM-16446	pyridopyrimidine		low
2-bromo-6-[1,4-dioxa-8-azaspiro[4.5]decan-8-yl(oxo)methyl]-11-pyrido[2,1-b]quinazolinone	pyridopyrimidine		low
LSM-16483	pyridopyrimidine		low
5-[[2-(diethylamino)-9-methyl-4-oxo-3-pyrido[1,2-a]pyrimidinyl]methylidene]-1,3-diazinane-2,4,6-trione	pyridopyrimidine		low
LSM-28172	pyridopyrimidine		low
3-ethyl-2-sulfanylidene-6,7,8,9-tetrahydro-1H-pyrimido[4,5-b]quinolin-4-one	pyridopyrimidine		low
8-(1-piperidinylsulfonyl)-6-pyrido[1,2-a]quinazolinone	pyridopyrimidine		low
pd 166866	biaryl; dimethoxybenzene; primary arylamine; pyridopyrimidine; ureas	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
palbociclib	aminopyridine; aromatic ketone; cyclopentanes; piperidines; pyridopyrimidine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	low
5-deazaflavin	pyridopyrimidine		low
1-(3,4-dimethylphenyl)-2,5-dioxo-3-dipyrido[1,2-d-3',4'-f]pyrimidinecarbonitrile	pyridopyrimidine		low
paliperidone palmitate	1,2-benzoxazoles; fatty acid ester; heteroarylpiperidine; organofluorine compound; pyridopyrimidine		low
ssr 69071	pyridopyrimidine		low
tgx 221	pyridopyrimidine		low
trametinib	acetamides; aromatic amine; cyclopropanes; organofluorine compound; organoiodine compound; pyridopyrimidine; ring assembly	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector	low
pamapimod	aromatic amine; aromatic ether; difluorobenzene; diol; primary alcohol; pyridopyrimidine; secondary amino compound	antirheumatic drug; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
2-imino-8-methyl-5-oxo-1-(2-oxolanylmethyl)-N-(2-phenylethyl)-3-dipyrido[1,2-d-3',4'-f]pyrimidinecarboxamide	pyridopyrimidine		low
ku 0063794	benzyl alcohols; monomethoxybenzene; morpholines; pyridopyrimidine; tertiary amino compound	antineoplastic agent; mTOR inhibitor	low
3-[(3-chlorophenyl)methyl]-5-ethoxy-1,6-dimethylpyrido[2,3-d]pyrimidine-2,4-dione	pyridopyrimidine		low
(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol	benzyl alcohols; morpholines; pyridopyrimidine; tertiary amino compound	antineoplastic agent; apoptosis inducer; mTOR inhibitor	low
kin-193	pyridopyrimidine		low
ly3009120	aminotoluene; aromatic amine; biaryl; monofluorobenzenes; phenylureas; pyridopyrimidine; secondary amino compound	antineoplastic agent; apoptosis inducer; autophagy inducer; B-Raf inhibitor; necroptosis inhibitor	low
sotorasib	acrylamides; methylpyridines; monofluorobenzenes; N-acylpiperazine; phenols; pyridopyrimidine; tertiary amino compound; tertiary carboxamide	antineoplastic agent	low

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	2000's	2010's
gamma-aminobutyric acid	1	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule	2007	2007	17.0	low	1	0
acetamide	1	acetamides; carboximidic acid; monocarboxylic acid amide; N-acylammonia		2007	2007	17.0	low	1	0
quinacrine	1	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor	2007	2007	17.0	low	1	0
catechol	1	catechols	allelochemical; genotoxin; plant metabolite	2007	2007	17.0	low	1	0
taxifolin	1	3'-hydroxyflavanones; 4'-hydroxyflavanones; dihydroflavonols; pentahydroxyflavanone; secondary alpha-hydroxy ketone		2007	2007	17.0	low	1	0
phosphonoacetic acid	1	monocarboxylic acid; phosphonic acids	antiviral agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor	2007	2007	17.0	low	1	0
3,4-dihydroxyphenylacetic acid	1	catechols; dihydroxyphenylacetic acid	human metabolite	2007	2007	17.0	low	1	0
aminocaproic acid	1	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite	2007	2007	17.0	low	1	0
diacetyl	1	alpha-diketone	Escherichia coli metabolite; Saccharomyces cerevisiae metabolite	2007	2007	17.0	low	1	0
hydroquinone	1	benzenediol; hydroquinones	antioxidant; carcinogenic agent; cofactor; Escherichia coli metabolite; human xenobiotic metabolite; mouse metabolite; skin lightening agent	2007	2007	17.0	low	1	0
melatonin	1	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger	2007	2007	17.0	low	1	0
n-acetylserotonin	1	acetamides; N-acylserotonin; phenols	antioxidant; human metabolite; mouse metabolite; tropomyosin-related kinase B receptor agonist	2007	2007	17.0	low	1	0
pyrazinamide	1	monocarboxylic acid amide; N-acylammonia; pyrazines	antitubercular agent; prodrug	2007	2007	17.0	low	1	0
quinolinic acid	1	pyridinedicarboxylic acid	Escherichia coli metabolite; human metabolite; mouse metabolite; NMDA receptor agonist	2007	2007	17.0	low	1	0
taurine	1	amino sulfonic acid; zwitterion	antioxidant; Escherichia coli metabolite; glycine receptor agonist; human metabolite; mouse metabolite; nutrient; radical scavenger; Saccharomyces cerevisiae metabolite	2007	2007	17.0	low	1	0
2-amino-5-phosphonovalerate	1	non-proteinogenic alpha-amino acid	NMDA receptor antagonist	2007	2007	17.0	low	1	0
alpha-methyl-4-carboxyphenylglycine	1			2007	2007	17.0	low	1	0
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid	1			2007	2007	17.0	low	1	0
1-hydroxy-3-amino-2-pyrrolidone	1			2007	2007	17.0	low	1	0
ibotenic acid	1	non-proteinogenic alpha-amino acid	neurotoxin	2007	2007	17.0	low	1	0
octoclothepine	1	dibenzothiepine		2019	2019	5.0	low	0	1
n(8)-bromoacetyl-n(1)-3'-(4-indolyloxy)-2'-hydroxypropyl-1,8-diamino-4-menthane	1			2007	2007	17.0	medium	1	0
sk&f-38393	1	benzazepine; catechols; secondary amino compound		2007	2007	17.0	low	1	0
vanilmandelic acid	1	2-hydroxy monocarboxylic acid; aromatic ether; phenols	human metabolite	2007	2007	17.0	low	1	0
1,10-diaminodecane	1			2007	2007	17.0	low	1	0
1,3-diethyl-8-phenylxanthine	1			2007	2007	17.0	low	1	0
1,3-dipropyl-8-cyclopentylxanthine	1	oxopurine	adenosine A1 receptor antagonist; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor	2007	2007	17.0	low	1	0
1,3-dipropyl-8-(4-sulfophenyl)xanthine	1			2007	2007	17.0	low	1	0
1,5-dihydroxyisoquinoline	1	isoquinolinol	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	2007	2007	17.0	low	1	0
pk 11195	2	aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes	antineoplastic agent	2007	2013	14.0	low	1	1
1-(2-trifluoromethylphenyl)imidazole	1	imidazoles		2007	2007	17.0	low	1	0
1-aminobenzotriazole	1			2007	2007	17.0	low	1	0
1-methylimidazole	1	imidazoles		2007	2007	17.0	low	1	0
edelfosine	1	glycerophosphocholine		2007	2007	17.0	low	1	0
pd 173074	1	aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist	2013	2013	11.0	low	0	1
1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one	1	oxadiazoloquinoxaline	EC 4.6.1.2 (guanylate cyclase) inhibitor	2007	2007	17.0	low	1	0
2,2'-dipyridyl	1	bipyridine	chelator; ferroptosis inhibitor	2007	2007	17.0	low	1	0
2-hydroxysaclofen	1	organochlorine compound		2007	2007	17.0	low	1	0
3,4-dichloroisocoumarin	1	isocoumarins; organochlorine compound	geroprotector; serine protease inhibitor	2007	2007	17.0	low	1	0
phaclofen	1	organophosphate oxoanion; zwitterion		2007	2007	17.0	low	1	0
3-aminobenzamide	1	benzamides; substituted aniline	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	2007	2007	17.0	low	1	0
3-bromo-7-nitroindazole	1			2007	2007	17.0	low	1	0
enprofylline	1	oxopurine	anti-arrhythmia drug; anti-asthmatic drug; bronchodilator agent; non-steroidal anti-inflammatory drug	2007	2007	17.0	low	1	0
3-nitropropionic acid	1	C-nitro compound	antimycobacterial drug; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor; mycotoxin; neurotoxin	2007	2007	17.0	low	1	0
4-amino-1,8-naphthalimide	1	benzoisoquinoline; dicarboximide		2007	2007	17.0	low	1	0
4-aminopyridine	1	aminopyridine; aromatic amine	avicide; orphan drug; potassium channel blocker	2007	2007	17.0	low	1	0
homovanillic acid	1	guaiacols; monocarboxylic acid	human metabolite; mouse metabolite	2007	2007	17.0	low	1	0
4-hydroxybenzoic acid hydrazide	1	carbohydrazide; phenols		2007	2007	17.0	low	1	0
4-phenyl-3-furoxancarbonitrile	1	1,2,5-oxadiazole; benzenes; N-oxide; nitrile	geroprotector; nitric oxide donor; platelet aggregation inhibitor; soluble guanylate cyclase activator; vasodilator agent	2007	2007	17.0	low	1	0
5,5-dimethyl-1-pyrroline-1-oxide	1	1-pyrroline nitrones	neuroprotective agent; spin trapping reagent	2007	2007	17.0	low	1	0
phenytoin	1	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent	2007	2007	17.0	low	1	0
5,7-dichlorokynurenic acid	1	quinolines		2007	2007	17.0	low	1	0
5-(n,n-hexamethylene)amiloride	1	aromatic amine; azepanes; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines	antineoplastic agent; apoptosis inducer; odorant receptor antagonist; sodium channel blocker	2007	2007	17.0	low	1	0
ethylisopropylamiloride	1	aromatic amine; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines; tertiary amino compound	anti-arrhythmia drug; neuroprotective agent; sodium channel blocker	2007	2007	17.0	low	1	0
5-fluoroindole-2-carboxylic acid	1	indolyl carboxylic acid		2007	2007	17.0	low	1	0
hydroxyindoleacetic acid	1	indole-3-acetic acids	drug metabolite; human metabolite; mouse metabolite	2007	2007	17.0	low	1	0
phenanthridone	1	lactam; phenanthridines	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; immunosuppressive agent; mutagen	2007	2007	17.0	low	1	0
6-chloromelatonin	1	acetamides		2007	2007	17.0	low	1	0
6-hydroxymelatonin	1	acetamides; tryptamines	metabolite; mouse metabolite	2007	2007	17.0	low	1	0
6-methoxytryptoline	1			2007	2007	17.0	low	1	0
6-nitroso-1,2-benzopyrone	1			2007	2007	17.0	low	1	0
7-chlorokynurenic acid	1	organochlorine compound; quinolinemonocarboxylic acid	neuroprotective agent; NMDA receptor antagonist	2007	2007	17.0	low	1	0
7-nitroindazole	1			2007	2007	17.0	low	1	0
8-(4-sulfophenyl)theophylline	1			2007	2007	17.0	low	1	0
8-cyclopentyl-1,3-dimethylxanthine	1	oxopurine		2007	2007	17.0	low	1	0
8-phenyltheophylline	1			2007	2007	17.0	low	1	0
abt 702	2	bipyridines		2013	2015	10.0	low	0	2
acetazolamide	1	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor	2007	2007	17.0	low	1	0
acetohexamide	1	acetophenones; N-sulfonylurea	hypoglycemic agent; insulin secretagogue	2007	2007	17.0	low	1	0
ag 127	1	nitrophenol		2007	2007	17.0	low	1	0
rtki cpd	1	aromatic ether; monochlorobenzenes; quinazolines	antineoplastic agent; antiviral agent; epidermal growth factor receptor antagonist; geroprotector	2007	2007	17.0	low	1	0
tyrphostin a23	1	catechols		2007	2007	17.0	low	1	0
tyrphostin 25	1	benzenetriol		2007	2007	17.0	low	1	0
tyrphostin a1	1	methoxybenzenes	geroprotector	2007	2007	17.0	low	1	0
1-aminoindan-1,5-dicarboxylic acid	1			2007	2007	17.0	low	1	0
albuterol	1	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic	2007	2007	17.0	low	1	0
alpha-methyltyrosine methyl ester	1			2007	2007	17.0	low	1	0
altretamine	1	triamino-1,3,5-triazine		2007	2007	17.0	low	1	0
amfonelic acid	1			2007	2007	17.0	low	1	0
amifostine anhydrous	1	diamine; organic thiophosphate	antioxidant; prodrug; radiation protective agent	2007	2007	17.0	low	1	0
theophylline	1	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent	2007	2007	17.0	low	1	0
amoxapine	1	dibenzooxazepine	adrenergic uptake inhibitor; antidepressant; dopaminergic antagonist; geroprotector; serotonin uptake inhibitor	2007	2007	17.0	low	1	0
aniracetam	1	N-acylpyrrolidine; pyrrolidin-2-ones		2007	2007	17.0	low	1	0
2-amino-4-phosphonobutyric acid	1			2007	2007	17.0	low	1	0
aspirin	1	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent	2007	2007	17.0	low	1	0
atenolol	1	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic	2007	2007	17.0	low	1	0
alpha-amino-3-hydroxy-5-tert-butyl-4-isoxazolepropionate	1	alpha-amino acid		2007	2007	17.0	low	1	0
aurintricarboxylic acid	1	monohydroxybenzoic acid; quinomethanes; tricarboxylic acid	fluorochrome; histological dye; insulin-like growth factor receptor 1 antagonist	2007	2007	17.0	low	1	0
azathioprine	1	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug	2007	2007	17.0	low	1	0
azelaic acid	1	alpha,omega-dicarboxylic acid; dicarboxylic fatty acid	antibacterial agent; antineoplastic agent; dermatologic drug; plant metabolite	2007	2007	17.0	low	1	0
baclofen	1	amino acid zwitterion; gamma-amino acid; monocarboxylic acid; monochlorobenzenes; primary amino compound	central nervous system depressant; GABA agonist; muscle relaxant	2007	2007	17.0	low	1	0
bay-k-8644	1	(trifluoromethyl)benzenes; C-nitro compound; dihydropyridine; methyl ester		2007	2007	17.0	low	1	0
benzamide	1	benzamides		2007	2007	17.0	low	1	0
bepridil	1	pyrrolidines; tertiary amine	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent	2007	2007	17.0	low	1	0
bicalutamide	1	(trifluoromethyl)benzenes; monocarboxylic acid amide; monofluorobenzenes; nitrile; sulfone; tertiary alcohol		2013	2013	11.0	low	0	1
bml 190	1	N-acylindole		2007	2007	17.0	low	1	0
brimonidine	1	imidazoles; quinoxaline derivative; secondary amine	adrenergic agonist; alpha-adrenergic agonist; antihypertensive agent	2007	2007	17.0	low	1	0
bumetanide	1	amino acid; benzoic acids; sulfonamide	diuretic; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor	2007	2007	17.0	low	1	0
bupivacaine	1	aromatic amide; piperidinecarboxamide; tertiary amino compound		2019	2019	5.0	low	0	1
caffeine	1	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic	2007	2007	17.0	low	1	0
verapamil	1	aromatic ether; nitrile; polyether; tertiary amino compound		2013	2013	11.0	low	0	1
carbamazepine	1	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic	2007	2007	17.0	low	1	0
carbetapentane	1	benzenes		2007	2007	17.0	low	1	0
carisoprodol	1	carbamate ester	muscle relaxant	2007	2007	17.0	low	1	0
carmustine	1	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent	2007	2007	17.0	low	1	0
celecoxib	1	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug	2013	2013	11.0	low	0	1
cgs 12066	1	N-arylpiperazine; organofluorine compound; pyrroloquinoxaline	serotonergic agonist	2007	2007	17.0	low	1	0
cgs 15943	1	aromatic amine; biaryl; furans; organochlorine compound; primary amino compound; quinazolines; triazoloquinazoline	adenosine A1 receptor antagonist; adenosine A2A receptor antagonist; antineoplastic agent; central nervous system stimulant	2007	2007	17.0	low	1	0
chelerythrine	1	benzophenanthridine alkaloid; organic cation	antibacterial agent; antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor	2013	2013	11.0	low	0	1
chlorambucil	1	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent	2007	2007	17.0	low	1	0
chlormezanone	1	1,3-thiazine; lactam; monochlorobenzenes; sulfone	antipsychotic agent; anxiolytic drug; muscle relaxant	2007	2007	17.0	low	1	0
chlorothiazide	1	benzothiadiazine	antihypertensive agent; diuretic	2007	2007	17.0	low	1	0
chlorpropamide	1	monochlorobenzenes; N-sulfonylurea	hypoglycemic agent; insulin secretagogue	2007	2007	17.0	low	1	0
chlorzoxazone	1	1,3-benzoxazoles; heteroaryl hydroxy compound; organochlorine compound	muscle relaxant; sedative	2007	2007	17.0	low	1	0
cilostamide	1	quinolines		2007	2007	17.0	low	1	0
cilostazol	1	lactam; tetrazoles	anticoagulant; bronchodilator agent; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; fibrin modulating drug; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent	2007	2007	17.0	low	1	0
cimetidine	1	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor	2007	2007	17.0	low	1	0
cinoxacin	1	cinnolines; oxacycle; oxo carboxylic acid	antibacterial drug; antiinfective agent	2007	2007	17.0	low	1	0
ciprofibrate	1	cyclopropanes; monocarboxylic acid; organochlorine compound	antilipemic drug	2007	2007	17.0	low	1	0
clofibrate	1	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist	2007	2007	17.0	low	1	0
clotrimazole	1	conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes	antiinfective agent; environmental contaminant; xenobiotic	2007	2007	17.0	low	1	0
cx546	1			2007	2007	17.0	low	1	0
cyclothiazide	1	benzothiadiazine	antihypertensive agent; diuretic	2007	2007	17.0	low	1	0
dephostatin	1			2007	2007	17.0	low	1	0
nonivamide	1	capsaicinoid; phenols	lachrymator	2007	2007	17.0	low	1	0
r 59022	1	diarylmethane		2007	2007	17.0	low	1	0
diazoxide	1	benzothiadiazine; organochlorine compound; sulfone	antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent	2007	2007	17.0	low	1	0
pentetic acid	1	pentacarboxylic acid	copper chelator	2007	2007	17.0	low	1	0
diphenyleneiodonium	1	organic cation		2007	2007	17.0	low	1	0
dipyridamole	1	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent	2007	2007	17.0	low	1	0
disopyramide	1	monocarboxylic acid amide; pyridines; tertiary amino compound	anti-arrhythmia drug	2007	2007	17.0	low	1	0
disulfiram	1	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor	2007	2007	17.0	low	1	0
2-amino-7-phosphonoheptanoic acid	1			2007	2007	17.0	low	1	0
thiorphan	1	N-acyl-amino acid		2007	2007	17.0	low	1	0
2,3-dimethoxy-1,4-naphthoquinone	1	1,4-naphthoquinones		2007	2007	17.0	low	1	0
domperidone	1	benzimidazoles; heteroarylpiperidine	antiemetic; dopaminergic antagonist	2007	2007	17.0	low	1	0
doxapram	1	morpholines; pyrrolidin-2-ones	central nervous system stimulant	2019	2019	5.0	low	0	1
droperidol	1	aromatic ketone; benzimidazoles; organofluorine compound	anaesthesia adjuvant; antiemetic; dopaminergic antagonist; first generation antipsychotic	2007	2007	17.0	low	1	0
ebselen	1	benzoselenazole	anti-inflammatory drug; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 3.5.4.1 (cytosine deaminase) inhibitor; EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor; enzyme mimic; ferroptosis inhibitor; genotoxin; hepatoprotective agent; neuroprotective agent; radical scavenger	2007	2007	17.0	low	1	0
ellipticine	1	indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound; polycyclic heteroarene	antineoplastic agent; plant metabolite	2007	2007	17.0	low	1	0
emodin	1	trihydroxyanthraquinone	antineoplastic agent; laxative; plant metabolite; tyrosine kinase inhibitor	2007	2007	17.0	low	1	0
ether	1	ether; volatile organic compound	inhalation anaesthetic; non-polar solvent; refrigerant	2019	2019	5.0	low	0	1
ethosuximide	1	dicarboximide; pyrrolidinone	anticonvulsant; geroprotector; T-type calcium channel blocker	2007	2007	17.0	low	1	0
etodolac	1	monocarboxylic acid; organic heterotricyclic compound	antipyretic; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug	2007	2007	17.0	low	1	0
felbamate	1	carbamate ester	anticonvulsant; neuroprotective agent	2007	2007	17.0	low	1	0
felodipine	1	dichlorobenzene; dihydropyridine; ethyl ester; methyl ester	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent	2007	2007	17.0	low	1	0
fenofibrate	1	aromatic ether; chlorobenzophenone; isopropyl ester; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic	2007	2007	17.0	low	1	0
flumazenil	1	ethyl ester; imidazobenzodiazepine; organofluorine compound	antidote to benzodiazepine poisoning; GABA antagonist	2007	2007	17.0	low	1	0
fluorouracil	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic	2007	2007	17.0	low	1	0
fluspirilene	1	diarylmethane		2007	2007	17.0	low	1	0
flutamide	1	(trifluoromethyl)benzenes; monocarboxylic acid amide	androgen antagonist; antineoplastic agent	2007	2007	17.0	low	1	0
formoterol fumarate	1	formamides; phenols; phenylethanolamines; secondary alcohol; secondary amino compound		2007	2007	17.0	low	1	0
fpl 64176	1	carboxylic ester; pyrroles	calcium channel agonist	2007	2007	17.0	low	1	0
furafylline	1	oxopurine		2007	2007	17.0	low	1	0
furosemide	2	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic	2007	2013	14.0	low	1	1
fusaric acid	1	aromatic carboxylic acid; pyridines		2007	2007	17.0	low	1	0
gabapentin	1	gamma-amino acid	anticonvulsant; calcium channel blocker; environmental contaminant; xenobiotic	2007	2007	17.0	low	1	0
4-amino-5-hexynoic acid	1			2007	2007	17.0	low	1	0
glipizide	1	aromatic amide; monocarboxylic acid amide; N-sulfonylurea; pyrazines	EC 2.7.1.33 (pantothenate kinase) inhibitor; hypoglycemic agent; insulin secretagogue	2007	2007	17.0	low	1	0
glyburide	2	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent	2007	2019	11.0	low	1	1
gossypol	1			2013	2013	11.0	low	0	1
1-(5-isoquinolinesulfonyl)piperazine	1	isoquinolines		2007	2007	17.0	low	1	0
fasudil	1	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent	2013	2013	11.0	low	0	1
haloperidol	1	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist	2007	2007	17.0	low	1	0
halothane	1	haloalkane; organobromine compound; organochlorine compound; organofluorine compound	inhalation anaesthetic	2019	2019	5.0	low	0	1
hemicholinium 3	1	morpholines		2007	2007	17.0	low	1	0
4-fluorohexahydrosiladifenidol	1			2007	2007	17.0	low	1	0
hydrochlorothiazide	1	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic	2007	2007	17.0	low	1	0
hydroxyurea	1	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent	2007	2007	17.0	low	1	0
ibudilast	1	pyrazolopyridine		2007	2007	17.0	low	1	0
ibuprofen	1	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic	2007	2007	17.0	low	1	0
ic 261	1	indoles		2007	2007	17.0	medium	1	0
lidocaine	1	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic	2019	2019	5.0	low	0	1
ifenprodil	1	piperidines		2007	2007	17.0	low	1	0
indirubin-3'-monoxime	2			2007	2013	14.0	low	1	1
indomethacin	1	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic	2007	2007	17.0	low	1	0
iodoacetamide	1			2007	2007	17.0	low	1	0
1-methyl-3-isobutylxanthine	1	3-isobutyl-1-methylxanthine		2007	2007	17.0	low	1	0
isoflurane	1	organofluorine compound	inhalation anaesthetic	2019	2019	5.0	low	0	1
4-piperidinecarboxylic acid	1			2007	2007	17.0	low	1	0
4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline	1			2007	2007	17.0	low	1	0
jl 18	1			2007	2007	17.0	low	1	0
nsc 664704	1	indolobenzazepine; lactam; organobromine compound	cardioprotective agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; geroprotector	2007	2007	17.0	low	1	0
ketamine	1	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic	2019	2019	5.0	low	0	1
ketoconazole	1	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine		2007	2007	17.0	low	1	0
ketoprofen	1	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic	2007	2007	17.0	low	1	0
kynurenic acid	1	monohydroxyquinoline; quinolinemonocarboxylic acid	G-protein-coupled receptor agonist; human metabolite; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist; Saccharomyces cerevisiae metabolite	2007	2007	17.0	low	1	0
2-amino-3-phosphonopropionic acid	1	alanine derivative; non-proteinogenic alpha-amino acid; phosphonic acids	human metabolite; metabotropic glutamate receptor antagonist	2007	2007	17.0	low	1	0
lamotrigine	1	1,2,4-triazines; dichlorobenzene; primary arylamine	anticonvulsant; antidepressant; antimanic drug; calcium channel blocker; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; excitatory amino acid antagonist; geroprotector; non-narcotic analgesic; xenobiotic	2007	2007	17.0	low	1	0
lansoprazole	1	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor	2007	2007	17.0	low	1	0
beta-lapachone	1	benzochromenone; orthoquinones	anti-inflammatory agent; antineoplastic agent; plant metabolite	2007	2007	17.0	low	1	0
leflunomide	2	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor	2007	2013	14.0	low	1	1
letrozole	1	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor	2013	2013	11.0	low	0	1
lg 100268	1			2013	2013	11.0	low	0	1
linopirdine	1	indoles		2007	2007	17.0	low	1	0
loratadine	2	benzocycloheptapyridine; ethyl ester; N-acylpiperidine; organochlorine compound; tertiary carboxamide	anti-allergic agent; cholinergic antagonist; geroprotector; H1-receptor antagonist	2007	2019	11.0	low	1	1
loxoprofen	1	cyclopentanones; monocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug	2007	2007	17.0	low	1	0
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one	1	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector	2007	2007	17.0	low	1	0
meclofenamate sodium anhydrous	1	organic sodium salt		2007	2007	17.0	low	1	0
mepivacaine	1	piperidinecarboxamide	drug allergen; local anaesthetic	2019	2019	5.0	low	0	1
metformin	1	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic	2013	2013	11.0	low	0	1
methiothepin	1	aryl sulfide; dibenzothiepine; N-alkylpiperazine; tertiary amino compound	antipsychotic agent; dopaminergic antagonist; geroprotector; serotonergic antagonist	2007	2007	17.0	low	1	0
methoctramine	1	aromatic ether; tetramine	muscarinic antagonist	2007	2007	17.0	low	1	0
nocodazole	1	aromatic ketone; benzimidazoles; carbamate ester; thiophenes	antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator	2007	2007	17.0	low	1	0
3-Hydroxy-alpha-methyl-DL-tyrosine	1	benzenes; monocarboxylic acid		2007	2007	17.0	low	1	0
metolazone	1	organochlorine compound; quinazolines; sulfonamide	antihypertensive agent; diuretic; ion transport inhibitor	2007	2007	17.0	low	1	0
milrinone	1	bipyridines; nitrile; pyridone	cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; platelet aggregation inhibitor; vasodilator agent	2007	2007	17.0	low	1	0
minoxidil	1	dialkylarylamine; tertiary amino compound		2007	2007	17.0	low	1	0
mitotane	1	diarylmethane		2007	2007	17.0	low	1	0
mitoxantrone	2	dihydroxyanthraquinone	analgesic; antineoplastic agent	2007	2013	14.0	low	1	1
ml 7	1	N-sulfonyldiazepane; organoiodine compound	EC 2.7.11.18 (myosin-light-chain kinase) inhibitor	2007	2007	17.0	low	1	0
entinostat	1	benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	2013	2013	11.0	low	0	1
n-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide	1	naphthalenes; organochlorine compound; primary amino compound; sulfonamide		2007	2007	17.0	low	1	0
n-bromoacetamide	1			2007	2007	17.0	low	1	0
ethylmaleimide	1	maleimides	anticoronaviral agent; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.1.1 (hexokinase) inhibitor	2007	2007	17.0	low	1	0
fg 7142	1	beta-carbolines		2007	2007	17.0	low	1	0
fenamic acid	1	aminobenzoic acid; secondary amino compound	membrane transport modulator	2007	2007	17.0	low	1	0
n 0840	1			2007	2007	17.0	low	1	0
nialamide	1	organonitrogen compound; organooxygen compound		2007	2007	17.0	low	1	0
niclosamide	1	benzamides; C-nitro compound; monochlorobenzenes; salicylanilides; secondary carboxamide	anthelminthic drug; anticoronaviral agent; antiparasitic agent; apoptosis inducer; molluscicide; piscicide; STAT3 inhibitor	2007	2007	17.0	low	1	0
nifedipine	1	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent	2007	2007	17.0	low	1	0
niflumic acid	1	aromatic carboxylic acid; pyridines		2007	2007	17.0	low	1	0
nilutamide	1	(trifluoromethyl)benzenes; C-nitro compound; imidazolidinone	androgen antagonist; antineoplastic agent	2007	2007	17.0	low	1	0
nimesulide	1	aromatic ether; C-nitro compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug	2007	2007	17.0	low	1	0
nimodipine	1	2-methoxyethyl ester; C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; isopropyl ester	antihypertensive agent; calcium channel blocker; cardiovascular drug; vasodilator agent	2007	2007	17.0	low	1	0
nipecotic acid	1	beta-amino acid; piperidinemonocarboxylic acid		2007	2007	17.0	low	1	0
nitrendipine	1	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent	2007	2007	17.0	low	1	0
masoprocol	1	catechols; lignan; tetrol	antioxidant; ferroptosis inhibitor; geroprotector; plant metabolite	2007	2007	17.0	low	1	0
5-nitro-2-(3-phenylpropylamino)benzoic acid	1	nitrobenzoic acid		2007	2007	17.0	low	1	0
ns 2028	1			2007	2007	17.0	low	1	0
ns 1619	1	(trifluoromethyl)benzenes; benzimidazoles; phenols	potassium channel opener	2007	2007	17.0	low	1	0
o(6)-benzylguanine	1			2007	2007	17.0	low	1	0
ofloxacin	1	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline		2007	2007	17.0	low	1	0
olomoucine	1	2,6-diaminopurines; ethanolamines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	2007	2007	17.0	low	1	0
olprinone	1	bipyridines		2013	2013	11.0	low	0	1
omeprazole	1	aromatic ether; benzimidazoles; pyridines; sulfoxide		2013	2013	11.0	low	0	1
oxaprozin	1	1,3-oxazoles; monocarboxylic acid	analgesic; non-steroidal anti-inflammatory drug	2007	2007	17.0	low	1	0
oxatomide	1	benzimidazoles; diarylmethane; N-alkylpiperazine	anti-allergic agent; anti-inflammatory agent; geroprotector; H1-receptor antagonist; serotonergic antagonist	2007	2007	17.0	low	1	0
oxiracetam	1	organonitrogen compound; organooxygen compound		2007	2007	17.0	low	1	0
oxolinic acid	1	aromatic carboxylic acid; organic heterotricyclic compound; oxacycle; quinolinemonocarboxylic acid; quinolone antibiotic	antibacterial drug; antifungal agent; antiinfective agent; antimicrobial agent; enzyme inhibitor	2007	2007	17.0	low	1	0
quinone	1	1,4-benzoquinones	cofactor; human xenobiotic metabolite; mouse metabolite	2007	2007	17.0	low	1	0
fenclonine	1	phenylalanine derivative		2007	2007	17.0	low	1	0
palmidrol	1	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-(saturated fatty acyl)ethanolamine	anti-inflammatory drug; anticonvulsant; antihypertensive agent; neuroprotective agent	2007	2007	17.0	low	1	0
1,7-dimethylxanthine	1	dimethylxanthine	central nervous system stimulant; human blood serum metabolite; human xenobiotic metabolite; mouse metabolite	2007	2007	17.0	low	1	0
pd 98059	1	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector	2007	2007	17.0	low	1	0
pentamidine	1	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic	2007	2007	17.0	low	1	0
pentobarbital	1	barbiturates	GABAA receptor agonist	2019	2019	5.0	low	0	1
pentoxifylline	1	oxopurine		2007	2007	17.0	low	1	0
perphenazine	1	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug	2007	2007	17.0	low	1	0
phenyl biguanide	1	guanidines	central nervous system drug	2007	2007	17.0	low	1	0
phenylbutazone	1	pyrazolidines	antirheumatic drug; EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor; metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug	2007	2007	17.0	low	1	0
phloretin	1	dihydrochalcones	antineoplastic agent; plant metabolite	2007	2007	17.0	low	1	0
picotamide	1	benzamides		2007	2007	17.0	low	1	0
pinacidil	1	pyridines		2007	2007	17.0	low	1	0
pindolol	1	indoles; secondary amine	antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; serotonergic antagonist; vasodilator agent	2007	2007	17.0	low	1	0
pioglitazone	1	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic	2013	2013	11.0	low	0	1
piperidine-4-sulfonic acid	1			2007	2007	17.0	low	1	0
piracetam	1	organonitrogen compound; organooxygen compound		2007	2007	17.0	low	1	0
pirenperone	1	aromatic ketone		2007	2007	17.0	low	1	0
praziquantel	1	isoquinolines		2007	2007	17.0	low	1	0
primidone	1	pyrimidone	anticonvulsant; environmental contaminant; xenobiotic	2007	2007	17.0	low	1	0
proglumide	1	benzamides; dicarboxylic acid monoamide; glutamine derivative; racemate	anti-ulcer drug; cholecystokinin antagonist; cholinergic antagonist; delta-opioid receptor agonist; drug metabolite; gastrointestinal drug; opioid analgesic; xenobiotic metabolite	2007	2007	17.0	low	1	0
propentofylline	1	oxopurine		2007	2007	17.0	low	1	0
propofol	1	phenols	anticonvulsant; antiemetic; intravenous anaesthetic; radical scavenger; sedative	2007	2007	17.0	low	1	0
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one	2	indoles		2013	2013	11.0	medium	0	2
pf 5901	1	quinolines		2007	2007	17.0	low	1	0
riluzole	2	benzothiazoles		2007	2013	14.0	low	1	1
risperidone	1	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine	alpha-adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; psychotropic drug; second generation antipsychotic; serotonergic antagonist	2007	2007	17.0	low	1	0
ritanserin	1	organofluorine compound; piperidines; thiazolopyrimidine	antidepressant; antipsychotic agent; anxiolytic drug; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist	2007	2007	17.0	low	1	0
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone	1	methoxybenzenes		2007	2007	17.0	low	1	0
rolipram	1	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor	2007	2007	17.0	low	1	0
salmeterol xinafoate	1	ether; phenols; primary alcohol; secondary alcohol; secondary amino compound		2007	2007	17.0	low	1	0
sb 206553	1	pyrroloindole		2013	2013	11.0	low	0	1
sb 220025	2	aminopyrimidine; imidazoles; organofluorine compound; piperidines	angiogenesis inhibitor; anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2013	2013	11.0	low	0	2
sb 202190	2	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2007	2013	14.0	low	1	1
sk&f 86002	2	imidazoles		2013	2013	11.0	low	0	2
sobuzoxane	1	organic molecular entity		2007	2007	17.0	low	1	0
spiroxatrine	1	imidazolidines		2007	2007	17.0	low	1	0
sq 22536	1	nucleoside analogue; oxolanes	EC 4.6.1.1 (adenylate cyclase) inhibitor	2007	2007	17.0	low	1	0
imatinib	1	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor	2013	2013	11.0	low	0	1
vorinostat	1	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	2013	2013	11.0	low	0	1
sulfaphenazole	1	primary amino compound; pyrazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial drug; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor; P450 inhibitor	2007	2007	17.0	low	1	0
sulfasalazine	1			2013	2013	11.0	low	0	1
sulpiride	1	benzamides; N-alkylpyrrolidine; sulfonamide	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist	2007	2007	17.0	low	1	0
t0156	1	naphthyridine derivative		2007	2007	17.0	low	1	0
2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine	1	stilbenoid		2013	2013	11.0	low	0	1
1,4-bis(2-(3,5-dichloropyridyloxy))benzene	1			2007	2007	17.0	low	1	0
terfenadine	1	diarylmethane		2007	2007	17.0	low	1	0
tetracaine	1	benzoate ester; tertiary amino compound	local anaesthetic	2019	2019	5.0	low	0	1
tetraethylammonium	1	quaternary ammonium ion		2019	2019	5.0	low	0	1
tetraisopropylpyrophosphamide	1	phosphoramide		2007	2007	17.0	low	1	0
thalidomide	1	phthalimides; piperidones		2007	2007	17.0	low	1	0
theobromine	1	dimethylxanthine	adenosine receptor antagonist; bronchodilator agent; food component; human blood serum metabolite; mouse metabolite; plant metabolite; vasodilator agent	2007	2007	17.0	low	1	0
8-(n,n-diethylamino)octyl-3,4,5-trimethoxybenzoate	1	trihydroxybenzoic acid		2007	2007	17.0	low	1	0
tolazamide	1	N-sulfonylurea	hypoglycemic agent; potassium channel blocker	2007	2007	17.0	low	1	0
tolbutamide	1	N-sulfonylurea	human metabolite; hypoglycemic agent; insulin secretagogue; potassium channel blocker	2007	2007	17.0	low	1	0
(1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid	1			2007	2007	17.0	low	1	0
ici 136,753	1	pyrazolopyridine		2007	2007	17.0	low	1	0
triamterene	1	pteridines	diuretic; sodium channel blocker	2007	2007	17.0	low	1	0
trimethoprim	1	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic	2007	2007	17.0	low	1	0
troglitazone	1	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent	2013	2013	11.0	low	0	1
tropicamide	1	acetamides		2007	2007	17.0	low	1	0
tyrphostin a9	1	alkylbenzene	geroprotector	2007	2007	17.0	low	1	0
vigabatrin	1	gamma-amino acid	anticonvulsant; EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor	2007	2007	17.0	low	1	0
8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine	1			2007	2007	17.0	low	1	0
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole	1	aromatic primary alcohol; furans; indazoles	antineoplastic agent; apoptosis inducer; platelet aggregation inhibitor; soluble guanylate cyclase activator; vasodilator agent	2007	2007	17.0	low	1	0
zardaverine	1	organofluorine compound; pyridazinone	anti-asthmatic drug; bronchodilator agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; peripheral nervous system drug	2007	2007	17.0	low	1	0
cortisone acetate	1	corticosteroid hormone		2007	2007	17.0	low	1	0
corticosterone	1	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite	2007	2007	17.0	low	1	0
reserpine	1	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic	2007	2007	17.0	low	1	0
procaine hydrochloride	1	organic molecular entity		2007	2007	17.0	low	1	0
isoproterenol hydrochloride	1	catechols		2007	2007	17.0	low	1	0
histamine dihydrochloride	1			2007	2007	17.0	low	1	0
carbachol	1	ammonium salt; carbamate ester	cardiotonic drug; miotic; muscarinic agonist; nicotinic acetylcholine receptor agonist; non-narcotic analgesic	2007	2007	17.0	low	1	0
spironolactone	1	3-oxo-Delta(4) steroid; oxaspiro compound; steroid lactone; thioester	aldosterone antagonist; antihypertensive agent; diuretic; environmental contaminant; xenobiotic	2007	2007	17.0	low	1	0
estrone	1	17-oxo steroid; 3-hydroxy steroid; phenolic steroid; phenols	antineoplastic agent; bone density conservation agent; estrogen; human metabolite; mouse metabolite	2007	2007	17.0	low	1	0
androsterone	1	17-oxo steroid; 3alpha-hydroxy steroid; androstanoid; C19-steroid	androgen; anticonvulsant; human blood serum metabolite; human metabolite; human urinary metabolite; mouse metabolite; pheromone	2007	2007	17.0	low	1	0
promazine hydrochloride	1	hydrochloride		2007	2007	17.0	low	1	0
pilocarpine hydrochloride	1	hydrochloride		2007	2007	17.0	low	1	0
dimethylphenylpiperazinium iodide	1	N-arylpiperazine; organic iodide salt; piperazinium salt; quaternary ammonium salt	nicotinic acetylcholine receptor agonist	2007	2007	17.0	low	1	0
pentylenetetrazole	1	organic heterobicyclic compound; organonitrogen heterocyclic compound		2007	2007	17.0	low	1	0
racepinephrine hydrochloride	1			2007	2007	17.0	low	1	0
(4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride	1			2007	2007	17.0	low	1	0
hexamethonium bromide	1			2007	2007	17.0	low	1	0
cystamine dihydrochloride	1			2007	2007	17.0	medium	1	0
cantharidin	1	cyclic dicarboxylic anhydride; monoterpenoid	EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; herbicide	2007	2007	17.0	low	1	0
tetraethylammonium chloride	1	organic chloride salt; quaternary ammonium salt	potassium channel blocker	2007	2007	17.0	low	1	0
aspartic acid	1	aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; mouse metabolite; neurotransmitter	2007	2007	17.0	low	1	0
glutamine	1	amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite	2007	2007	17.0	low	1	0
vincristine	1	acetate ester; formamides; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; drug; microtubule-destabilising agent; plant metabolite; tubulin modulator	2007	2007	17.0	low	1	0
physostigmine	1	carbamate ester; indole alkaloid	antidote to curare poisoning; EC 3.1.1.8 (cholinesterase) inhibitor; miotic	2007	2007	17.0	low	1	0
apomorphine	1	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug	2007	2007	17.0	low	1	0
promethazine hydrochloride	1	hydrochloride	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; geroprotector; H1-receptor antagonist; local anaesthetic; sedative	2007	2007	17.0	low	1	0
bromodeoxyuridine	1	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent	2007	2007	17.0	low	1	0
levodopa	1	amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug	2007	2007	17.0	low	1	0
methoxamine hydrochloride	1	dimethoxybenzene		2007	2007	17.0	low	1	0
papaverine hydrochloride	1			2007	2007	17.0	low	1	0
bretylium tosylate	1	organosulfonate salt; quaternary ammonium salt	adrenergic antagonist; anti-arrhythmia drug; antihypertensive agent	2007	2007	17.0	low	1	0
berlition	1	dithiolanes; heterocyclic fatty acid; lipoic acid; thia fatty acid	cofactor; nutraceutical; prosthetic group	2007	2007	17.0	low	1	0
methacholine chloride	1	quaternary ammonium salt		2007	2007	17.0	low	1	0
androstenedione	1	17-oxo steroid; 3-oxo-Delta(4) steroid; androstanoid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite	2007	2007	17.0	low	1	0
colchicine	1	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen	2007	2007	17.0	low	1	0
yohimbine hydrochloride	1			2007	2007	17.0	low	1	0
gallamine triethiodide	1			2007	2007	17.0	low	1	0
cycloheximide	1	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor	2007	2007	17.0	low	1	0
egtazic acid	1	diether; tertiary amino compound; tetracarboxylic acid	chelator	2007	2007	17.0	low	1	0
cycloserine	1	4-amino-1,2-oxazolidin-3-one; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic; zwitterion	antiinfective agent; antimetabolite; antitubercular agent; metabolite; NMDA receptor agonist	2007	2007	17.0	low	1	0
17-alpha-hydroxyprogesterone	1	17alpha-hydroxy-C21-steroid; 17alpha-hydroxy steroid; tertiary alpha-hydroxy ketone	human metabolite; metabolite; mouse metabolite; progestin	2007	2007	17.0	low	1	0
quinacrine monohydrochloride	1			2007	2007	17.0	medium	1	0
chlorpromazine hydrochloride	1	hydrochloride; phenothiazines	anticoronaviral agent; phenothiazine antipsychotic drug	2007	2007	17.0	low	1	0
cytarabine hydrochloride	1			2007	2007	17.0	low	1	0
tryptophan	1	erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; tryptophan zwitterion; tryptophan	antidepressant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite	2007	2007	17.0	low	1	0
lidocaine hydrochloride	1	hydrochloride	anti-arrhythmia drug; local anaesthetic	2007	2007	17.0	low	1	0
arginine	1	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical	2007	2007	17.0	low	1	0
rotenone	1	organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin	2007	2007	17.0	low	1	0
synephrine	1	ethanolamines; phenethylamine alkaloid; phenols	alpha-adrenergic agonist; plant metabolite	2007	2007	17.0	low	1	0
pyridostigmine bromide	1	pyridinium salt		2007	2007	17.0	low	1	0
imipramine hydrochloride	1	hydrochloride	antidepressant	2007	2007	17.0	low	1	0
neostigmine bromide	1	bromide salt		2007	2007	17.0	low	1	0
edrophonium chloride	1	chloride salt; quaternary ammonium salt	antidote; diagnostic agent; EC 3.1.1.8 (cholinesterase) inhibitor	2007	2007	17.0	low	1	0
suramin sodium	1	organic sodium salt	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug	2007	2007	17.0	low	1	0
pyrazolanthrone	1	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector	2007	2007	17.0	low	1	0
methapyrilene hydrochloride	1	hydrochloride	anti-allergic agent; carcinogenic agent; H1-receptor antagonist; sedative	2007	2007	17.0	low	1	0
tetrracaine hydrochloride	1	benzoate ester		2007	2007	17.0	low	1	0
chelidamic acid	1			2007	2007	17.0	low	1	0
2-chloroadenosine	1	purine nucleoside		2007	2007	17.0	low	1	0
diphenhydramine hydrochloride	1	hydrochloride; organoammonium salt	anti-allergic agent; antiemetic; antiparkinson drug; antipruritic drug; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; sedative	2007	2007	17.0	low	1	0
cysteamine hydrochloride	1			2007	2007	17.0	low	1	0
propantheline bromide	1	xanthenes		2007	2007	17.0	low	1	0
hydralazine hydrochloride	1	hydrochloride	antihypertensive agent; vasodilator agent	2007	2007	17.0	low	1	0
ethamivan	1	methoxybenzenes; phenols		2007	2007	17.0	low	1	0
pargyline hydrochloride	1			2007	2007	17.0	low	1	0
aminophylline	1	mixture	bronchodilator agent; cardiotonic drug	2007	2007	17.0	low	1	0
azacitidine	2	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent	2007	2013	14.0	low	1	1
orphenadrine hydrochloride	1	hydrochloride	antiparkinson drug; H1-receptor antagonist; muscarinic antagonist; muscle relaxant; NMDA receptor antagonist; parasympatholytic	2007	2007	17.0	low	1	0
betamethasone	1	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic agent; anti-inflammatory drug; immunosuppressive agent	2007	2007	17.0	low	1	0
benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide	1			2007	2007	17.0	low	1	0
cyproterone acetate	1	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; chlorinated steroid; steroid ester	androgen antagonist; geroprotector; progestin	2007	2007	17.0	low	1	0
bicuculline	1	benzylisoquinoline alkaloid; isoquinoline alkaloid; isoquinolines	agrochemical; central nervous system stimulant; GABA-gated chloride channel antagonist; GABAA receptor antagonist; neurotoxin	2007	2007	17.0	low	1	0
kainic acid	1	dicarboxylic acid; L-proline derivative; non-proteinogenic L-alpha-amino acid; pyrrolidinecarboxylic acid	antinematodal drug; excitatory amino acid agonist	2007	2007	17.0	low	1	0
podophyllotoxin	2	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator	2007	2013	14.0	low	1	1
tetrahydrozoline hydrochloride	1	hydrochloride	nasal decongestant; sympathomimetic agent; vasoconstrictor agent	2007	2007	17.0	low	1	0
dequalinium chloride	1	organic chloride salt	antifungal agent; antineoplastic agent; antiseptic drug; mitochondrial NADH:ubiquinone reductase inhibitor	2007	2007	17.0	low	1	0
decamethonium dibromide	1			2007	2007	17.0	low	1	0
amitriptyline hydrochloride	1	organic tricyclic compound		2007	2007	17.0	low	1	0
naphazoline hydrochloride	1	organic molecular entity		2007	2007	17.0	low	1	0
doxylamine succinate	1	organic molecular entity		2007	2007	17.0	low	1	0
carbamylhydrazine monohydrochloride	1	organic molecular entity		2007	2007	17.0	medium	1	0
formestane	2	17-oxo steroid; 3-oxo-Delta(4) steroid; enol; hydroxy steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor	2007	2013	14.0	low	1	1
debrisoquin sulfate	1	organic sulfate salt		2007	2007	17.0	low	1	0
betaine hydrochloride	1			2007	2007	17.0	low	1	0
bethanechol chloride	1	carbamate ester; chloride salt; quaternary ammonium salt	muscarinic agonist	2007	2007	17.0	low	1	0
acetylcysteine	1	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary	2007	2007	17.0	low	1	0
hydroxychloroquine sulfate	1			2013	2013	11.0	low	0	1
Mecamylamine hydrochloride	1	monoterpenoid		2007	2007	17.0	medium	1	0
vinblastine	1			2007	2007	17.0	low	1	0
cyproheptadine hydrochloride (anhydrous)	1	hydrochloride		2007	2007	17.0	low	1	0
5 alpha-androstane-3 alpha,17 beta-diol	1	androstane-3alpha,17beta-diol	Daphnia magna metabolite; human metabolite	2007	2007	17.0	low	1	0
amiloride hydrochloride, anhydrous	1	hydrochloride	diuretic; sodium channel blocker	2013	2013	11.0	low	0	1
pimozide	1	benzimidazoles; heteroarylpiperidine; organofluorine compound	antidyskinesia agent; dopaminergic antagonist; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist	2007	2007	17.0	low	1	0
azetidyl-2-carboxylic acid	1	azetidine-2-carboxylic acid		2007	2007	17.0	low	1	0
muscarine	1			2007	2007	17.0	medium	1	0
antazoline hydrochloride	1			2007	2007	17.0	low	1	0
acadesine	1	1-ribosylimidazolecarboxamide; aminoimidazole; nucleoside analogue	antineoplastic agent; platelet aggregation inhibitor	2013	2013	11.0	low	0	1
doxifluridine	1	organofluorine compound; pyrimidine 5'-deoxyribonucleoside	antimetabolite; antineoplastic agent; prodrug	2007	2007	17.0	low	1	0
meclofenoxate hydrochloride	1			2007	2007	17.0	low	1	0
clonidine hydrochloride	1	dichlorobenzene		2007	2007	17.0	low	1	0
cladribine	1	organochlorine compound; purine 2'-deoxyribonucleoside	antineoplastic agent; immunosuppressive agent	2013	2013	11.0	low	0	1
beclomethasone	1	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; corticosteroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic drug; anti-inflammatory drug	2007	2007	17.0	low	1	0
buthionine sulfoximine	1	diastereoisomeric mixture; homocysteines; non-proteinogenic alpha-amino acid; sulfoximide	EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor; ferroptosis inducer	2007	2007	17.0	low	1	0
mexiletine hydrochloride	1	hydrochloride	anti-arrhythmia drug	2007	2007	17.0	low	1	0
cyclophosphamide	1	hydrate	alkylating agent; antineoplastic agent; carcinogenic agent; immunosuppressive agent	2007	2007	17.0	low	1	0
suxamethonium chloride	1	chloride salt	muscle relaxant	2007	2007	17.0	low	1	0
cyclobenzaprine hydrochloride	1	hydrochloride	antidepressant; muscle relaxant	2007	2007	17.0	low	1	0
n-methylaspartate	1	amino dicarboxylic acid; D-alpha-amino acid; D-aspartic acid derivative; secondary amino compound	neurotransmitter agent	2007	2007	17.0	low	1	0
3-deazaadenosine	1			2007	2007	17.0	low	1	0
metoclopramide hydrochloride	1			2007	2007	17.0	low	1	0
isoetharine mesylate	1			2007	2007	17.0	low	1	0
zalcitabine	1	pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor	2007	2007	17.0	low	1	0
cesium chloride	1	inorganic caesium salt; inorganic chloride	phase-transfer catalyst; vasoconstrictor agent	2019	2019	5.0	low	0	1
propionylpromazine hydrochloride	1			2007	2007	17.0	low	1	0
camptothecin	1	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite	2007	2007	17.0	low	1	0
nsc-145,668	1	hydrochloride	antimetabolite; antineoplastic agent	2007	2007	17.0	medium	1	0
clodronic acid	1	1,1-bis(phosphonic acid); one-carbon compound; organochlorine compound	antineoplastic agent; bone density conservation agent	2007	2007	17.0	low	1	0
benserazide hydrochloride	1	hydrochloride	antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor	2007	2007	17.0	low	1	0
pancuronium bromide	1	bromide salt	cholinergic antagonist; muscle relaxant; nicotinic antagonist	2007	2007	17.0	medium	1	0
tetradecanoylphorbol acetate	1	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator	2007	2007	17.0	low	1	0
danazol	1	17beta-hydroxy steroid; terminal acetylenic compound	anti-estrogen; estrogen antagonist; geroprotector	2007	2007	17.0	low	1	0
metergoline	1	carbamate ester; ergoline alkaloid	dopamine agonist; geroprotector; serotonergic antagonist	2007	2007	17.0	low	1	0
lisuride	1	monocarboxylic acid amide	antidyskinesia agent; antiparkinson drug; dopamine agonist; serotonergic agonist	2007	2007	17.0	low	1	0
disopyramide phosphate	1	organoammonium phosphate		2007	2007	17.0	low	1	0
bromocriptine	1	indole alkaloid	antidyskinesia agent; antiparkinson drug; dopamine agonist; hormone antagonist	2007	2007	17.0	low	1	0
ergocristine	1	ergot alkaloid		2007	2007	17.0	low	1	0
triamcinolone	1	11beta-hydroxy steroid; 16alpha-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug	2007	2007	17.0	low	1	0
zidovudine	2	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor	2007	2013	14.0	low	1	1
paclitaxel	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent	2007	2007	17.0	low	1	0
buspirone hydrochloride	1	hydrochloride	anxiolytic drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; sedative; serotonergic agonist	2007	2007	17.0	low	1	0
etoposide	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor	2007	2007	17.0	low	1	0
propafenone hydrochloride	1	hydrochloride	anti-arrhythmia drug	2007	2007	17.0	low	1	0
etazolate hydrochloride	1			2007	2007	17.0	low	1	0
butaclamol	1	amino alcohol; organic heteropentacyclic compound; tertiary alcohol; tertiary amino compound	dopaminergic antagonist	2007	2007	17.0	low	1	0
etidocaine	1	amino acid amide	local anaesthetic	2019	2019	5.0	low	0	1
ribavirin	1	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor	2007	2007	17.0	low	1	0
carbidopa	1	catechols; hydrate; hydrazines; monocarboxylic acid	antidyskinesia agent; antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor	2007	2007	17.0	low	1	0
cephradine	1	beta-lactam antibiotic allergen; cephalosporin	antibacterial drug	2007	2007	17.0	low	1	0
methyldopa	1	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	alpha-adrenergic agonist; antihypertensive agent; hapten; peripheral nervous system drug; sympatholytic agent	2007	2007	17.0	low	1	0
lonidamine	2	dichlorobenzene; indazoles; monocarboxylic acid	antineoplastic agent; antispermatogenic agent; EC 2.7.1.1 (hexokinase) inhibitor; geroprotector	2007	2013	14.0	low	1	1
dexibuprofen	1	ibuprofen	non-narcotic analgesic; non-steroidal anti-inflammatory drug	2007	2007	17.0	low	1	0
quisqualic acid	1	non-proteinogenic alpha-amino acid		2007	2007	17.0	low	1	0
pirfenidone	1	pyridone	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug	2007	2007	17.0	low	1	0
flecainide acetate	1	acetate salt	anti-arrhythmia drug	2007	2007	17.0	low	1	0
nicardipine hydrochloride	1	dihydropyridine	geroprotector	2007	2007	17.0	low	1	0
idarubicin	1	anthracycline antibiotic; deoxy hexoside; monosaccharide derivative		2007	2007	17.0	low	1	0
captopril	1	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	2007	2007	17.0	low	1	0
terazosin hydrochloride anhydrous	1			2007	2007	17.0	low	1	0
pergolide mesylate	1	methanesulfonate salt	antiparkinson drug; dopamine agonist; geroprotector	2007	2007	17.0	low	1	0
ranitidine hydrochloride	1			2007	2007	17.0	medium	1	0
colforsin	1	acetate ester; cyclic ketone; labdane diterpenoid; organic heterotricyclic compound; tertiary alpha-hydroxy ketone; triol	adenylate cyclase agonist; anti-HIV agent; antihypertensive agent; plant metabolite; platelet aggregation inhibitor; protein kinase A agonist	2007	2007	17.0	low	1	0
cefaclor anhydrous	1	cephalosporin	antibacterial drug; drug allergen	2007	2007	17.0	low	1	0
alo 2145	1	hydrochloride	alpha-adrenergic agonist; antiglaucoma drug	2007	2007	17.0	medium	1	0
enoximone	1	aromatic ketone		2007	2007	17.0	low	1	0
piritrexim	1			2015	2015	9.0	low	0	1
simvastatin	1	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug	2013	2013	11.0	low	0	1
atomoxetine	1	aromatic ether; secondary amino compound; toluenes	adrenergic uptake inhibitor; antidepressant; environmental contaminant; xenobiotic	2007	2007	17.0	low	1	0
raloxifene hydrochloride	1	hydrochloride	bone density conservation agent; estrogen antagonist; estrogen receptor modulator	2007	2007	17.0	low	1	0
mifepristone	1	3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound	abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive	2007	2007	17.0	low	1	0
itraconazole	1	aromatic ether; conazole antifungal drug; cyclic ketal; dichlorobenzene; dioxolane; N-arylpiperazine; triazole antifungal drug; triazoles	EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; Hedgehog signaling pathway inhibitor; P450 inhibitor	2013	2013	11.0	low	0	1
quinpirole hydrochloride	1			2007	2007	17.0	low	1	0
imazodan	1			2007	2007	17.0	low	1	0
pravadoline	1			2013	2013	11.0	low	0	1
zileuton	1	1-benzothiophenes; ureas	anti-asthmatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor; leukotriene antagonist; non-steroidal anti-inflammatory drug	2013	2013	11.0	low	0	1
niguldipine	1	diarylmethane		2013	2013	11.0	low	0	1
mibefradil dihydrochloride	2			2007	2019	11.0	medium	1	1
topotecan	1	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor	2013	2013	11.0	low	0	1
eliprodil	1	monochlorobenzenes; monofluorobenzenes; piperidines; secondary alcohol; tertiary amino compound		2013	2013	11.0	low	0	1
gemcitabine	1	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic	2013	2013	11.0	low	0	1
aptiganel hydrochloride	1			2007	2007	17.0	low	1	0
adenosine	1	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent	2007	2007	17.0	low	1	0
phenelzine sulfate	1	organic molecular entity		2007	2007	17.0	low	1	0
fluoxetine hydrochloride	1	hydrochloride; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine		2007	2007	17.0	low	1	0
propranolol hydrochloride	1	hydrochloride		2007	2007	17.0	low	1	0
bupropion hydrochloride	1	aromatic ketone		2007	2007	17.0	low	1	0
diltiazem hydrochloride	1	hydrochloride	antihypertensive agent; calcium channel blocker; vasodilator agent	2007	2007	17.0	low	1	0
trazodone hydrochloride	1	hydrochloride	adrenergic antagonist; antidepressant; H1-receptor antagonist; sedative; serotonin uptake inhibitor	2007	2007	17.0	low	1	0
verapamil hydrochloride	2			2007	2013	14.0	low	1	1
doxazosin mesylate	1	methanesulfonate salt	geroprotector	2007	2007	17.0	low	1	0
terfenadine	1	diarylmethane		2007	2007	17.0	low	1	0
efavirenz	1	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor	2013	2013	11.0	low	0	1
amantadine hydrochloride	1	hydrochloride	antiviral agent; dopamine agonist; NMDA receptor antagonist	2007	2007	17.0	low	1	0
mevastatin	2	2-pyranones; carboxylic ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	antifungal agent; apoptosis inducer; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; fungal metabolite; Penicillium metabolite	2007	2019	11.0	low	1	1
chloroquine diphosphate	1			2007	2007	17.0	low	1	0
dobutamine hydrochloride	1	hydrochloride	beta-adrenergic agonist; cardiotonic drug; sympathomimetic agent	2007	2007	17.0	low	1	0
desipramine hydrochloride	1	hydrochloride	drug allergen	2007	2007	17.0	low	1	0
dopamine hydrochloride	1	catecholamine		2007	2007	17.0	low	1	0
proadifen hydrochloride	1			2007	2007	17.0	low	1	0
4-nitrobenzylthioinosine	1	purine nucleoside		2007	2007	17.0	low	1	0
bendamustine	1	benzimidazoles		2013	2013	11.0	low	0	1
caroverine	1	quinoxaline derivative		2013	2013	11.0	low	0	1
metrifudil	1			2007	2007	17.0	low	1	0
rutecarpine	1	beta-carbolines		2007	2007	17.0	low	1	0

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays.
PloS one, , Volume: 8, Issue:3, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays.
PloS one, , Volume: 8, Issue:3, 2013

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays.
PloS one, , Volume: 8, Issue:3, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays.
PloS one, , Volume: 8, Issue:3, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays.
PloS one, , Volume: 8, Issue:3, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays.
PloS one, , Volume: 8, Issue:3, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays.
PloS one, , Volume: 8, Issue:3, 2013

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays.
PloS one, , Volume: 8, Issue:3, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays.
PloS one, , Volume: 8, Issue:3, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays.
PloS one, , Volume: 8, Issue:3, 2013

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays.
PloS one, , Volume: 8, Issue:3, 2013

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

TASK Channels Pharmacology: New Challenges in Drug Design.
Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays.
PloS one, , Volume: 8, Issue:3, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays.
PloS one, , Volume: 8, Issue:3, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays.
PloS one, , Volume: 8, Issue:3, 2013

Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	2000's	2010's
ha14-1	1	1-benzopyran		2007	2007	17.0	low	1	0
tyrphostin a9	1	alkylbenzene	geroprotector	2010	2010	14.0	low	1	0
9,10-dimethyl-1,2-benzanthracene	2	ortho-fused polycyclic arene; tetraphenes	carcinogenic agent	2007	2008	16.5	low	2	0
tolonium chloride	1			2005	2005	19.0	low	1	0
pyrroles	1	pyrrole; secondary amine		2007	2007	17.0	low	1	0
quinazolines	14	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines		2005	2013	15.4	low	12	2
malondialdehyde	1	dialdehyde	biomarker	2009	2009	15.0	low	1	0
paclitaxel	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent	2006	2006	18.0	low	1	0
gefitinib	1	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist	2005	2005	19.0	low	1	0
lapatinib	1	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor	2007	2007	17.0	low	1	0
tamoxifen	1	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator	2010	2010	14.0	low	1	0
dinoprostone	1	prostaglandins E	human metabolite; mouse metabolite; oxytocic	2008	2008	16.0	low	1	0
gw 583340	1			2012	2012	12.0	medium	0	1
gx 15-070	1			2007	2007	17.0	low	1	0

Condition	Studies	First Year	Last Year	Average Age	Relationship Strength	2000's	2010's
Anemia, Fanconi	1	2016	2016	8.0	low	0	1
Astrocytoma, Grade IV	1	2013	2013	11.0	low	0	1
Benign Neoplasms	2	2007	2008	16.5	low	2	0
Benign Neoplasms, Brain	1	2013	2013	11.0	low	0	1
Body Weight	2	2005	2009	17.0	low	2	0
Brain Neoplasms	1	2013	2013	11.0	low	0	1
Breast Cancer	1	2007	2007	17.0	low	1	0
Breast Neoplasms	1	2007	2007	17.0	low	1	0
Cancer of Gallbladder	1	2005	2005	19.0	low	1	0
Cancer of Lung	1	2009	2009	15.0	low	1	0
Cancer of Mouth	2	2007	2008	16.5	low	2	0
Cancer of Ovary	1	2006	2006	18.0	low	1	0
Cancer of Prostate	1	2010	2010	14.0	low	1	0
Cancer of Skin	1	2010	2010	14.0	low	1	0
Carcinoma	2	2005	2010	16.5	low	2	0
Carcinoma, Anaplastic	2	2005	2010	16.5	low	2	0
Carcinoma, Epidermoid	2	2007	2008	16.5	low	2	0
Carcinoma, Non-Small Cell Lung	1	2009	2009	15.0	low	1	0
Carcinoma, Non-Small-Cell Lung	1	2009	2009	15.0	low	1	0
Carcinoma, Squamous Cell	2	2007	2008	16.5	low	2	0
Cell Transformation, Neoplastic	2	2008	2010	15.0	low	2	0
Congenital Zika Syndrome	1	2020	2020	4.0	low	0	1
Contact Dermatitis	1	2019	2019	5.0	low	0	1
Dermatitis, Contact	1	2019	2019	5.0	low	0	1
Disease Exacerbation	1	2010	2010	14.0	low	1	0
Disease Models, Animal	5	2001	2020	13.6	low	3	2
Epithelial Neoplasms	1	2010	2010	14.0	low	1	0
Ewing Sarcoma	1	2010	2010	14.0	low	1	0
Experimental Neoplasms	1	2005	2005	19.0	low	1	0
Fanconi Anemia	1	2016	2016	8.0	low	0	1
Gallbladder Neoplasms	1	2005	2005	19.0	low	1	0
Glioblastoma	1	2013	2013	11.0	low	0	1
Invasiveness, Neoplasm	1	2013	2013	11.0	low	0	1
Itching	1	2019	2019	5.0	low	0	1
Left Ventricular Dysfunction	1	2009	2009	15.0	low	1	0
Lung Neoplasms	1	2009	2009	15.0	low	1	0
Malaria, Falciparum	1	2014	2014	10.0	low	0	1
Mouth Neoplasms	2	2007	2008	16.5	low	2	0
Neoplasms	2	2007	2008	16.5	low	2	0
Ovarian Neoplasms	1	2006	2006	18.0	low	1	0
Plasmodium falciparum Malaria	1	2014	2014	10.0	low	0	1
Prostatic Neoplasms	1	2010	2010	14.0	low	1	0
Pruritus	1	2019	2019	5.0	low	0	1
Sarcoma, Ewing	1	2010	2010	14.0	low	1	0
Sensitivity and Specificity	1	2007	2007	17.0	low	1	0
Skin Neoplasms	1	2010	2010	14.0	low	1	0
Soft Tissue Neoplasms	1	2010	2010	14.0	low	1	0
Ventricular Dysfunction, Left	1	2009	2009	15.0	low	1	0
Zika Virus Infection	1	2020	2020	4.0	low	0	1

Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Proceedings of the National Academy of Sciences of the United States of America, , 12-08, Volume: 117, Issue:49, 2020

Differential effects of low- and high-dose GW2974, a dual epidermal growth factor receptor and HER2 kinase inhibitor, on glioblastoma multiforme invasion.
Journal of neuroscience research, , Volume: 91, Issue:1, 2013

Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
Oncology reports, , Volume: 17, Issue:2, 2007

Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content.
Oncology reports, , Volume: 24, Issue:1, 2010

Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 11, Issue:15, 2005

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells.
British journal of cancer, , Mar-24, Volume: 100, Issue:6, 2009

Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch by topical application of a dual inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 tyrosine kinases.
Oral oncology, , Volume: 44, Issue:7, 2008

[Inhibiting effects of GW2974 on DMBA-induced hamster buccal pouch carcinogenesis].
Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology, , Volume: 42, Issue:7, 2007

Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Science translational medicine, , 07-10, Volume: 11, Issue:500, 2019

A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
Journal of biomolecular screening, , Volume: 21, Issue:6, 2016

Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 11, Issue:15, 2005

Differential effects of low- and high-dose GW2974, a dual epidermal growth factor receptor and HER2 kinase inhibitor, on glioblastoma multiforme invasion.
Journal of neuroscience research, , Volume: 91, Issue:1, 2013

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells.
British journal of cancer, , Mar-24, Volume: 100, Issue:6, 2009

Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch by topical application of a dual inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 tyrosine kinases.
Oral oncology, , Volume: 44, Issue:7, 2008

[Inhibiting effects of GW2974 on DMBA-induced hamster buccal pouch carcinogenesis].
Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology, , Volume: 42, Issue:7, 2007

Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells.
Cell cycle (Georgetown, Tex.), , Jun-15, Volume: 7, Issue:12, 2008

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents.
Biochemical pharmacology, , Oct-16, Volume: 72, Issue:8, 2006

Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content.
Oncology reports, , Volume: 24, Issue:1, 2010

Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Science translational medicine, , 07-10, Volume: 11, Issue:500, 2019

Establishment, characterization, and drug sensitivity of a new Ewing sarcoma cell line (SS-ES-1).
Journal of pediatric hematology/oncology, , Volume: 32, Issue:8, 2010

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Dual inhibition of both the epidermal growth factor receptor and erbB2 effectively inhibits the promotion of skin tumors during two-stage carcinogenesis.
Cancer prevention research (Philadelphia, Pa.), , Volume: 3, Issue:8, 2010

Establishment, characterization, and drug sensitivity of a new Ewing sarcoma cell line (SS-ES-1).
Journal of pediatric hematology/oncology, , Volume: 32, Issue:8, 2010

A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
Journal of biomolecular screening, , Volume: 19, Issue:6, 2014

Endurance exercise training preserves cardiac function in rats receiving doxorubicin and the HER-2 inhibitor GW2974.
Cancer chemotherapy and pharmacology, , Volume: 64, Issue:6, 2009

Dual inhibition of both the epidermal growth factor receptor and erbB2 effectively inhibits the promotion of skin tumors during two-stage carcinogenesis.
Cancer prevention research (Philadelphia, Pa.), , Volume: 3, Issue:8, 2010

Endurance exercise training preserves cardiac function in rats receiving doxorubicin and the HER-2 inhibitor GW2974.
Cancer chemotherapy and pharmacology, , Volume: 64, Issue:6, 2009

Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Proceedings of the National Academy of Sciences of the United States of America, , 12-08, Volume: 117, Issue:49, 2020

Endurance exercise training preserves cardiac function in rats receiving doxorubicin and the HER-2 inhibitor GW2974.
Cancer chemotherapy and pharmacology, , Volume: 64, Issue:6, 2009

Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 11, Issue:15, 2005

Differential effects of low- and high-dose GW2974, a dual epidermal growth factor receptor and HER2 kinase inhibitor, on glioblastoma multiforme invasion.
Journal of neuroscience research, , Volume: 91, Issue:1, 2013

Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
Oncology reports, , Volume: 17, Issue:2, 2007

Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content.
Oncology reports, , Volume: 24, Issue:1, 2010

Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 11, Issue:15, 2005

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells.
British journal of cancer, , Mar-24, Volume: 100, Issue:6, 2009

Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch by topical application of a dual inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 tyrosine kinases.
Oral oncology, , Volume: 44, Issue:7, 2008

[Inhibiting effects of GW2974 on DMBA-induced hamster buccal pouch carcinogenesis].
Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology, , Volume: 42, Issue:7, 2007

Dual inhibition of both the epidermal growth factor receptor and erbB2 effectively inhibits the promotion of skin tumors during two-stage carcinogenesis.
Cancer prevention research (Philadelphia, Pa.), , Volume: 3, Issue:8, 2010

Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch by topical application of a dual inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 tyrosine kinases.
Oral oncology, , Volume: 44, Issue:7, 2008

Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Science translational medicine, , 07-10, Volume: 11, Issue:500, 2019

Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Proceedings of the National Academy of Sciences of the United States of America, , 12-08, Volume: 117, Issue:49, 2020

Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Science translational medicine, , 07-10, Volume: 11, Issue:500, 2019

[Inhibiting effects of GW2974 on DMBA-induced hamster buccal pouch carcinogenesis].
Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology, , Volume: 42, Issue:7, 2007

Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 11, Issue:15, 2005

Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
Bioorganic & medicinal chemistry letters, , Jun-04, Volume: 11, Issue:11, 2001

A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
Journal of biomolecular screening, , Volume: 21, Issue:6, 2016

Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 11, Issue:15, 2005

Differential effects of low- and high-dose GW2974, a dual epidermal growth factor receptor and HER2 kinase inhibitor, on glioblastoma multiforme invasion.
Journal of neuroscience research, , Volume: 91, Issue:1, 2013

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells.
British journal of cancer, , Mar-24, Volume: 100, Issue:6, 2009

Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch by topical application of a dual inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 tyrosine kinases.
Oral oncology, , Volume: 44, Issue:7, 2008

[Inhibiting effects of GW2974 on DMBA-induced hamster buccal pouch carcinogenesis].
Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology, , Volume: 42, Issue:7, 2007

Differential effects of low- and high-dose GW2974, a dual epidermal growth factor receptor and HER2 kinase inhibitor, on glioblastoma multiforme invasion.
Journal of neuroscience research, , Volume: 91, Issue:1, 2013

Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells.
Cell cycle (Georgetown, Tex.), , Jun-15, Volume: 7, Issue:12, 2008

Chemical genetics reveals a complex functional ground state of neural stem cells.
Nature chemical biology, , Volume: 3, Issue:5, 2007

Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 11, Issue:15, 2005

Dual inhibition of both the epidermal growth factor receptor and erbB2 effectively inhibits the promotion of skin tumors during two-stage carcinogenesis.
Cancer prevention research (Philadelphia, Pa.), , Volume: 3, Issue:8, 2010

Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents.
Biochemical pharmacology, , Oct-16, Volume: 72, Issue:8, 2006

Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content.
Oncology reports, , Volume: 24, Issue:1, 2010

Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Science translational medicine, , 07-10, Volume: 11, Issue:500, 2019

Establishment, characterization, and drug sensitivity of a new Ewing sarcoma cell line (SS-ES-1).
Journal of pediatric hematology/oncology, , Volume: 32, Issue:8, 2010

Dual inhibition of both the epidermal growth factor receptor and erbB2 effectively inhibits the promotion of skin tumors during two-stage carcinogenesis.
Cancer prevention research (Philadelphia, Pa.), , Volume: 3, Issue:8, 2010

A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
Journal of biomolecular screening, , Volume: 19, Issue:6, 2014

gw2974

Description

Cross-References

Synonyms (53)

Drug Classes (1)

Protein Targets (82)

Potency Measurements

Inhibition Measurements

Other Measurements

Bioassays (58)

Research

Studies (35)

Study Types

Bioavailability (1)

Dosage (1)

Interactions (1)

gw2974

Description

Cross-References

Synonyms (53)

Drug Classes (1)

Protein Targets (82)

Potency Measurements

Inhibition Measurements

Other Measurements

Bioassays (58)

Research

Studies (35)

Study Types

Related Drugs (1,368)

Drugs in this Class (73)

Drugs Involved in Assays Together (1,292)

Drugs Researched Together (14)

Related Conditions (49)

Bioavailability (1)

Dosage (1)

Interactions (1)